Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Aug 5, 2013

What the Top 15 Biopharma CEOs Are Making

Who are the highest-paid executives this year?

What the Top 15 Biopharma CEOs Are Making

The CEOs from Roche and Sanofi joined Novartis in raising the presence of non-U.S. companies on the list this year. [© Tijana - Fotolia.com]

  • #8. Joseph Jimenez

    Company: Novartis

    Full title: CEO

    2012 Compensation: $14,196,551 (CHF: 13,228,188)1

    2011 Compensation: $16,874,192 (CHF: 15,722,386)1

    % Change: -15.9%

    Position on 2012 List: #6

  • #7. John C. Lechleiter, Ph.D.

    Company: Eli Lilly

    Full title: Chairman of the Board, President, and CEO

    2012 Compensation: $14,620,633

    2011 Compensation: $16,370,094

    % Change: -10.7%

    Position on 2012 List: #5

  • #6. John C. Martin

    Company: Gilead Sciences

    Full title: Chairman of the Board and CEO

    2012 Compensation: $15,257,272

    2011 Compensation: $15,615,645

    % Change: -2.3%

    Position on 2012 List: #7

  • #5. Kenneth C. Frazier

    Company: Merck & Co.

    Full title: Chairman of the Board, President, and CEO

    2012 Compensation: $15,459,607

    2011 Compensation: $13,347,652

    % Change: 15.8%

    Position on 2012 List: #10

  • #4. Lamberto Andreotti

    Company: Bristol-Myers Squibb

    Full title: CEO

    2012 Compensation: $17,201,980

    2011 Compensation: $14,911,947

    % Change: 15.4%

    Position on 2012 List: #8

  • #3. Ian Read

    Company: Pfizer

    Full title: Chairman of the Board and CEO

    2012 Compensation: $25,634,136

    2011 Compensation: $25,013,348

    % Change: 2.5%

    Position on 2012 List: #2

  • #2. William C. Weldon

    Company: Johnson & Johnson

    Full title: Chairman of the Board until December 28, 2012; CEO until April 26, 2012

    2012 Compensation: $29,838,259

    2011 Compensation: $26,797,939

    % Change: 11.3%

    Position on 2012 List: #1

  • #1. Leonard S. Schleifer, M.D., Ph.D.

    Company: Regeneron

    Full title: President and CEO

    2012 Compensation: $30,047,0972

    2011 Compensation: $10,562,661

    % Change: 184.5%

    Position on 2012 List: Not ranked



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »